New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
13:05 EDTABTAbbott says over 2,000 patients to be included in phase 3 program for HCV
Abbott released details on its phase 3 hepatitis C registrational program following results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease in Boston. Topline intent-to-treat results from the 12-week, triple-DAA regimens with ribavirin presented at the AASLD meeting this week found that 97.5%, or 77 of 79, of treatment-na´ve GT1 patients and 93.3%, or 42 of 45, in GT1 null responder patients achieved SVR12. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals, with and without ribavirin, for the treatment of HCV in genotype 1 non-cirrhotic, treatment-na´ve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks. The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r, ABT-267 and ABT-333. Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials, the company said.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
10:00 EDTABTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Buy from Hold at ISI Group... Abbott (ABT) upgraded to Buy from Hold at Deutsche Bank... Ahold (AHONY) upgraded to Overweight from Neutral at JPMorgan... Alere (ALR) upgraded to Buy from Hold at Craig-Hallum... Ambev (ABEV) upgraded to Buy from Neutral at Goldman... Bayer (BAYRY) upgraded to Outperform from Market Perform at Bernstein... C.H. Robinson (CHRW) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Outperform from Neutral at Macquarie... HCC Insurance (HCC) upgraded at Raymond James... Hannon Armstrong (HASI) upgraded to Buy from Neutral at BofA/Merrill... Jamba (JMBA) upgraded to Outperform from Neutral at Wedbush... Midway Gold (MDW) upgraded to Speculative Buy from Hold at Canaccord... PG&E (PCG) upgraded to Buy from Hold at Deutsche Bank... RWE AG (RWEOY) upgraded to Neutral from Underweight at JPMorgan... Starwood (HOT) upgraded to Buy from Hold at Craig-Hallum... Total System (TSS) upgraded to Overweight from Equal Weight at Stephens.
09:31 EDTABTAbbott acquires Topera
Subscribe for More Information
07:22 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:55 EDTABTAbbott upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
October 28, 2014
07:50 EDTABTAbbott management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
06:22 EDTABTMylan, Abbott enter into amendment, still see deal closing in 1Q15
Subscribe for More Information
October 22, 2014
09:24 EDTABTAbbott says on track for another year of double digit adjusted EPS growth
Subscribe for More Information
09:21 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:16 EDTABTAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
09:14 EDTABTAbbott sees FY14 operational sales growth in the mid single digits
Sees foreign exchange to have negative impact of approx. 2% on FY reported sales, somewhat more negative than previous expectations. Sees FY14 reported sales growth in low to mid single digits. Sees FY gross margin ratio about 55% of sales. Comments made on the Q3 earnings conference call.
08:04 EDTABTAbbott raises FY14 adjusted EPS view to $2.25-$2.27 from $2.19-$2.29
Subscribe for More Information
07:37 EDTABTAbbott sees Q4 EPS excl items 68c-70c, consensus 70c
Subscribe for More Information
07:36 EDTABTAbbott reports Q3 Nutrition revenue $1.79B, Q3 Diagnostics revenue $1.19B
Subscribe for More Information
07:34 EDTABTAbbott reports Q3 EPS 62c, consensus 59c
Subscribe for More Information
October 21, 2014
15:35 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use